WuXi Biologics signed an exclusive development agreement with German healthcare company Fresenius, providing exclusive options to develop up to 37 biosimilar candidates over the next decade. The partnership could expand Fresenius's existing pipeline from 29 to as many as 66 molecules across 13 therapeutic areas, including oncology, immunology, neurology, and cardiopulmonary medicine, with initial development focused on treatments for lymphoma and thyroid eye disease. The fee-for-service agreement allows Fresenius to scale research and development spending as individual projects advance while retaining global commercialization rights and the economic benefits of successful products.
